Showing results (841-850 of 3,150) with videos related to

Sort By:
Pageof 315
Neuro-Oncology|June 4, 2011
Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histologyAndré O von Bueren, Katja von Hoff, Torsten Pietsch, et al.
Neuro-Oncology|July 19, 2011
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiformeRen-Yuan Bai, Verena Staedtke, Colette M Aprhys, et al.
Neuro-Oncology|July 23, 2011
AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomasMatthew L Bush, Janet Oblinger, Victoria Brendel, et al.
Neuro-Oncology|August 18, 2011
ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1Bryan W Day, Brett W Stringer, Mark D Spanevello, et al.
Neuro-Oncology|August 3, 2011
Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastomaOliver Bähr, Elke Hattingen, Johannes Rieger, et al.
Neuro-Oncology|August 23, 2011
Prognostic variables in oligodendroglial tumors: a single-institution study of 95 casesDavid Scheie, Torstein R Meling, Milada Cvancarova, et al.
Neuro-Oncology|August 23, 2011
Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumabBenjamin M Ellingson, Timothy F Cloughesy, Albert Lai, et al.
Neuro-Oncology|August 5, 2011
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?Jennifer L Clarke, Michele M Ennis, W K Alfred Yung, et al.
Neuro-Oncology|August 26, 2011
MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomasInas S Khayal, Scott R Vandenberg, Kenneth J Smith, et al.
Neuro-Oncology|May 12, 2011
Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathwayIchiro Nakano, Kaushal Joshi, Koppany Visnyei, et al.
Pageof 315